CytomX Therapeutics, Inc. short interest in 2026
In 2026, CytomX Therapeutics, Inc.'s disclosed short interest ran from 9.47% of shares outstanding on 15 Jan 2026 to 17.73% on 15 Sep 2026, a change of +8.26 percentage points. The year's high was 18.52% on 15 Jul 2026 and its low 8.70% on 30 Jan 2026, averaging 13.85% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.93 days on 14 Aug 2026. Full history: CytomX Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 9.47% (15 Jan 2026)
- End of year
- 17.73% (15 Sep 2026)
- Change
- +8.26 pp
- High
- 18.52% (15 Jul 2026)
- Low
- 8.70% (30 Jan 2026)
- Average
- 13.85%
- Highest days to cover
- 15.93 (14 Aug 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 9.47% | 7.49 | |
| 30 Jan 2026 | 8.70% | 3.33 | |
| 13 Feb 2026 | 9.97% | 4.66 | |
| 27 Feb 2026 | 11.08% | 8.03 | |
| 13 Mar 2026 | 12.00% | 7.10 | |
| 31 Mar 2026 | 12.95% | 1.14 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 16.17% | 5.41 | |
| 30 Apr 2026 | 13.66% | 8.44 | |
| 15 May 2026 | 14.30% | 10.32 | 10-Q filed, results (8-K) |
| 29 May 2026 | 13.19% | 9.31 | |
| 15 Jun 2026 | 14.06% | 8.65 | |
| 30 Jun 2026 | 16.34% | 4.32 | |
| 15 Jul 2026 | 18.52% | 10.38 | |
| 31 Jul 2026 | 16.11% | 11.78 | |
| 14 Aug 2026 | 15.89% | 15.93 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 15.38% | 11.81 | |
| 15 Sep 2026 | 17.73% | 9.29 |
See also: CytomX Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.